Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort

Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxicities referred to as immune-related adverse events (irAE). Here we describe the clinical presentation and management of rheumatic immune-related adverse events (Rh-irAE) in a national multi-center cohort. All patients presenting with Rh-irAE at 9 academic sites across Canada between January 2013 and January 2019 were...